Predictors of fatigue 30 days after completing anthracycline plus taxane adjuvant chemotherapy for breast cancer

Kimberly K. Wielgus, Ann Malone Berger, Melody Hertzog

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purposes/Objectives: To identify the predictors of fatigue 30 days after completing adjuvant chemotherapy for breast cancer and whether differences are observed between a behavioral sleep intervention and a healthy-eating attention control group in predicting fatigue. Design: Descriptive, exploratory, secondary analysis of a randomized clinical trial. Setting: Outpatient oncology patients in a midwestern U.S. city. Sample: 96 women, ages 29-83 years, 72% married, 95% white, diagnosed with stage I-IIIA breast cancer, receiving adjuvant anthracycline and taxane chemotherapy. Methods: Participants were randomized to a behavioral sleep intervention group or an attention control group. Participants completed data collection prior to and during the peak and rebound days of the initial chemotherapy treatment cycle and after the last treatment. Main Research Variables: Fatigue, circadian rhythms of activity, objective and subjective sleep-wake, and objective and subjective activity-rest. Findings: Predictors of fatigue were less total sleep time prior to treatment, higher fatigue prior to treatment and at the peak, and less energy upon awakening on rebound days. In the control group, predictors of higher fatigue were higher fatigue prior to treatment, higher body mass index, higher number of positive lymph nodes, and less daytime dysfunction. For the intervention group, lower peak activity at the peak of initial treatment differentially predicted fatigue. Conclusions: Results suggest the sleep intervention group participants who maintained activity balanced with sleep at the peak of the initial treatment benefited most from the intervention. Implications for Nursing: Nurses should screen for fatigue prior to initial chemotherapy treatment and at regular intervals, further assess for poor sleep in patients who report fatigue of 4 or higher (on a 0-10 scale), and use evidence-based guidelines to select appropriate interventions.

Original languageEnglish (US)
Pages (from-to)38-48
Number of pages11
JournalOncology nursing forum
Volume36
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Anthracyclines
Adjuvant Chemotherapy
Fatigue
Breast Neoplasms
Sleep
Therapeutics
Drug Therapy
Control Groups
taxane
Circadian Rhythm
Body Mass Index
Nursing
Outpatients
Randomized Controlled Trials
Lymph Nodes
Nurses
Guidelines

ASJC Scopus subject areas

  • Oncology(nursing)

Cite this

Predictors of fatigue 30 days after completing anthracycline plus taxane adjuvant chemotherapy for breast cancer. / Wielgus, Kimberly K.; Berger, Ann Malone; Hertzog, Melody.

In: Oncology nursing forum, Vol. 36, No. 1, 01.01.2009, p. 38-48.

Research output: Contribution to journalArticle

@article{e51a5edaef614bb9b7a4abd0fbe3704b,
title = "Predictors of fatigue 30 days after completing anthracycline plus taxane adjuvant chemotherapy for breast cancer",
abstract = "Purposes/Objectives: To identify the predictors of fatigue 30 days after completing adjuvant chemotherapy for breast cancer and whether differences are observed between a behavioral sleep intervention and a healthy-eating attention control group in predicting fatigue. Design: Descriptive, exploratory, secondary analysis of a randomized clinical trial. Setting: Outpatient oncology patients in a midwestern U.S. city. Sample: 96 women, ages 29-83 years, 72{\%} married, 95{\%} white, diagnosed with stage I-IIIA breast cancer, receiving adjuvant anthracycline and taxane chemotherapy. Methods: Participants were randomized to a behavioral sleep intervention group or an attention control group. Participants completed data collection prior to and during the peak and rebound days of the initial chemotherapy treatment cycle and after the last treatment. Main Research Variables: Fatigue, circadian rhythms of activity, objective and subjective sleep-wake, and objective and subjective activity-rest. Findings: Predictors of fatigue were less total sleep time prior to treatment, higher fatigue prior to treatment and at the peak, and less energy upon awakening on rebound days. In the control group, predictors of higher fatigue were higher fatigue prior to treatment, higher body mass index, higher number of positive lymph nodes, and less daytime dysfunction. For the intervention group, lower peak activity at the peak of initial treatment differentially predicted fatigue. Conclusions: Results suggest the sleep intervention group participants who maintained activity balanced with sleep at the peak of the initial treatment benefited most from the intervention. Implications for Nursing: Nurses should screen for fatigue prior to initial chemotherapy treatment and at regular intervals, further assess for poor sleep in patients who report fatigue of 4 or higher (on a 0-10 scale), and use evidence-based guidelines to select appropriate interventions.",
author = "Wielgus, {Kimberly K.} and Berger, {Ann Malone} and Melody Hertzog",
year = "2009",
month = "1",
day = "1",
doi = "10.1188/09.ONF.38-48",
language = "English (US)",
volume = "36",
pages = "38--48",
journal = "Oncology Nursing Forum",
issn = "0190-535X",
publisher = "Oncology Nursing Society",
number = "1",

}

TY - JOUR

T1 - Predictors of fatigue 30 days after completing anthracycline plus taxane adjuvant chemotherapy for breast cancer

AU - Wielgus, Kimberly K.

AU - Berger, Ann Malone

AU - Hertzog, Melody

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Purposes/Objectives: To identify the predictors of fatigue 30 days after completing adjuvant chemotherapy for breast cancer and whether differences are observed between a behavioral sleep intervention and a healthy-eating attention control group in predicting fatigue. Design: Descriptive, exploratory, secondary analysis of a randomized clinical trial. Setting: Outpatient oncology patients in a midwestern U.S. city. Sample: 96 women, ages 29-83 years, 72% married, 95% white, diagnosed with stage I-IIIA breast cancer, receiving adjuvant anthracycline and taxane chemotherapy. Methods: Participants were randomized to a behavioral sleep intervention group or an attention control group. Participants completed data collection prior to and during the peak and rebound days of the initial chemotherapy treatment cycle and after the last treatment. Main Research Variables: Fatigue, circadian rhythms of activity, objective and subjective sleep-wake, and objective and subjective activity-rest. Findings: Predictors of fatigue were less total sleep time prior to treatment, higher fatigue prior to treatment and at the peak, and less energy upon awakening on rebound days. In the control group, predictors of higher fatigue were higher fatigue prior to treatment, higher body mass index, higher number of positive lymph nodes, and less daytime dysfunction. For the intervention group, lower peak activity at the peak of initial treatment differentially predicted fatigue. Conclusions: Results suggest the sleep intervention group participants who maintained activity balanced with sleep at the peak of the initial treatment benefited most from the intervention. Implications for Nursing: Nurses should screen for fatigue prior to initial chemotherapy treatment and at regular intervals, further assess for poor sleep in patients who report fatigue of 4 or higher (on a 0-10 scale), and use evidence-based guidelines to select appropriate interventions.

AB - Purposes/Objectives: To identify the predictors of fatigue 30 days after completing adjuvant chemotherapy for breast cancer and whether differences are observed between a behavioral sleep intervention and a healthy-eating attention control group in predicting fatigue. Design: Descriptive, exploratory, secondary analysis of a randomized clinical trial. Setting: Outpatient oncology patients in a midwestern U.S. city. Sample: 96 women, ages 29-83 years, 72% married, 95% white, diagnosed with stage I-IIIA breast cancer, receiving adjuvant anthracycline and taxane chemotherapy. Methods: Participants were randomized to a behavioral sleep intervention group or an attention control group. Participants completed data collection prior to and during the peak and rebound days of the initial chemotherapy treatment cycle and after the last treatment. Main Research Variables: Fatigue, circadian rhythms of activity, objective and subjective sleep-wake, and objective and subjective activity-rest. Findings: Predictors of fatigue were less total sleep time prior to treatment, higher fatigue prior to treatment and at the peak, and less energy upon awakening on rebound days. In the control group, predictors of higher fatigue were higher fatigue prior to treatment, higher body mass index, higher number of positive lymph nodes, and less daytime dysfunction. For the intervention group, lower peak activity at the peak of initial treatment differentially predicted fatigue. Conclusions: Results suggest the sleep intervention group participants who maintained activity balanced with sleep at the peak of the initial treatment benefited most from the intervention. Implications for Nursing: Nurses should screen for fatigue prior to initial chemotherapy treatment and at regular intervals, further assess for poor sleep in patients who report fatigue of 4 or higher (on a 0-10 scale), and use evidence-based guidelines to select appropriate interventions.

UR - http://www.scopus.com/inward/record.url?scp=58149484519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149484519&partnerID=8YFLogxK

U2 - 10.1188/09.ONF.38-48

DO - 10.1188/09.ONF.38-48

M3 - Article

VL - 36

SP - 38

EP - 48

JO - Oncology Nursing Forum

JF - Oncology Nursing Forum

SN - 0190-535X

IS - 1

ER -